Check out Brigham Buhler's statement here: My inbox was full of comments from people who watched yesterday
Protocol approach 2: gut-focused autoimmune support (BPC-157 plus KPV) Goal: Restore gut barrier integrity and reduce intestinal inflammation Components: BPC-157 : 200-300 mcg twice daily, orally or subcutaneously near the abdomen (promotes mucosal healing, angiogenesis) KPV: 200-500 mcg daily, orally (NF-kB inhibition, cytokine reduction, PepT1-mediated gut absorption) Rationale: For autoimmune conditions with significant gastrointestinal involvement, including IBD, celiac-associated inflammation, or any autoimmune condition complicated by leaky gut, this combination addresses both the physical barrier damage (BPC-157) and the inflammatory signaling (KPV)
A 5 mg vial of BPC-157 reconstituted with 2 mL of water yields 2.5 mg/mL, and a typical 250 mcg dose is only 10 units
This guide walks through what the before and after timeline actually looks like at 3, 6, and 12 months, what determines the magnitude of your results, and who is the right candidate for this protocol
Retatrutide Dosage: Titration Schedule Retatrutide dosage chart with weekly titration schedule
As reflected in Table 166 of this final rule with comment period, we estimate that OPPS payments to governmental hospitals (including State and local governmental hospitals) will increase by 2.1 percent under this final rule with comment period
